VINELBINE
Manufacturer Details
FRESENIUS KABI
Fresenius Kabi Onchology Ltd
Echelon Institutional Area
Plot No 11 Sector 32
Gurgoan 122001
Compositions:
Vinorelbine tartrate 10mg per ml injection,
|
Strength
|
Rate
|
Packing Style
|
|
10mg per ml inj.
|
2741.00
|
1ml injection
|
|
10mg per ml inj.
|
11653.00
|
5ml injection
|
List of Related Indications:
List Of Drugs:
- Vinorelbine tartrate-@ - Vinca Alkaloids - Mitotic inhibitors- (Dec 1994)
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Mitotic inhibitors include-
Etoposide, Vincristine, Vinblastine, Teniposide, Vinorelbine tartarate
Interacting drugs-summary
+ Vinorelbine -
Cisplatin
incidence of granulocytopenia with vinorelbine used in combination with cisplatin is significantly higher with than with single - agent vinorelbine
Mitomycin
acute pulmonary reactions have been reported with vinorelbine and other anticaner vinca alkaloids used in conjunction with mitomycin
Indication:
Non-small lung cancer
Mitotic inhibitors include-
Etoposide, Vincristine, Vinblastine, Teniposide, Vinorelbine tartarate
Approved by FDA on December 23, 1994
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Vinorelbin Tarttrate Anti-cancer 17-01-2001
Adverse Reaction:
Granulocytopenia. Mild to moderate peripheral neuropathy.
Alopecia. Mild to moderate nausea.
Chest pain, shortage of breath. Fatigue.
Contra-Indications:
Patients with pretreatment granulocyte counts less than 1000cells/mm3
Special precautions:
Monitoring white blood counts. Bonr marrow .
Bronchospasm
acute shortage of breath. Eye contact.
Dosages/ Overdosage Etc:
Approved by FDA on December 23, 1994
Indications:
Non-small lung cancer
Dosage:
The usual initial dose is 30mg/m2 administered weekly. The recommended method of administration is an IV injection over 6 to 10 minutes.
Patient Information:
Mitotic inhibitors include-
Etoposide, Vincristine, Vinblastine, Teniposide, Vinorelbine tartarate
1. Inform patients that the major acute toxicites of vinorelbine are related to bone marrow toxicity, specially granulocytopenia with increased susceptibility to infection.
2. Advise woman of child bearing potential to avoid pregnancy during treatment
Pharmacology/ Pharmacokinetics:
Pharmacology:
Vinorelbine is a semi-synthetic vinca alkaloid with antitumor activity that interferes with microtubule assembly.
Pharmacokinetics:
Vinorelbine undergoes substantial hepatic elimination, with large amounts recovered in feces. The binding to plasma constituents in cancer patients ranged from 79.6% to 91.2%. Vinorelbine binding was not altered in the presence of cisplatin.
Pregnancy and lactation:
Pregnancy:
Advise woman of child bearing potential to avoid becoming pregnant during therapy with vinorelbine.
Lactation:
Nursing should be discontinued in woman who are receiving vinorelbine therapy.
